101 related articles for article (PubMed ID: 23528729)
1. Quantifying the importance of pMHC valency, total pMHC dose and frequency on nanoparticle therapeutic efficacy.
Sugarman J; Tsai S; Santamaria P; Khadra A
Immunol Cell Biol; 2013 May; 91(5):350-9. PubMed ID: 23528729
[TBL] [Abstract][Full Text] [Related]
2. On how monospecific memory-like autoregulatory CD8+ T cells can blunt diabetogenic autoimmunity: a computational approach.
Khadra A; Tsai S; Santamaria P; Edelstein-Keshet L
J Immunol; 2010 Nov; 185(10):5962-72. PubMed ID: 20962260
[TBL] [Abstract][Full Text] [Related]
3. Autoimmunity treatment using pMHC-NP-based therapy: designing nanoparticle treatment of autoimmunity with quantitative biology.
Schnell S; Pietropaolo M
Immunol Cell Biol; 2013 May; 91(5):333-4. PubMed ID: 23609902
[No Abstract] [Full Text] [Related]
4. Reversal of autoimmunity by boosting memory-like autoregulatory T cells.
Tsai S; Shameli A; Yamanouchi J; Clemente-Casares X; Wang J; Serra P; Yang Y; Medarova Z; Moore A; Santamaria P
Immunity; 2010 Apr; 32(4):568-80. PubMed ID: 20381385
[TBL] [Abstract][Full Text] [Related]
5. Structural and functional characterization of a single-chain peptide-MHC molecule that modulates both naive and activated CD8+ T cells.
Samanta D; Mukherjee G; Ramagopal UA; Chaparro RJ; Nathenson SG; DiLorenzo TP; Almo SC
Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13682-7. PubMed ID: 21825122
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-mediated targeting of autoantigen peptide to cross-presenting liver sinusoidal endothelial cells protects from CD8 T-cell-driven autoimmune cholangitis.
Carambia A; Gottwick C; Schwinge D; Stein S; Digigow R; Şeleci M; Mungalpara D; Heine M; Schuran FA; Corban C; Lohse AW; Schramm C; Heeren J; Herkel J
Immunology; 2021 Apr; 162(4):452-463. PubMed ID: 33346377
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice.
Carambia A; Freund B; Schwinge D; Bruns OT; Salmen SC; Ittrich H; Reimer R; Heine M; Huber S; Waurisch C; Eychmüller A; Wraith DC; Korn T; Nielsen P; Weller H; Schramm C; Lüth S; Lohse AW; Heeren J; Herkel J
J Hepatol; 2015 Jun; 62(6):1349-56. PubMed ID: 25617499
[TBL] [Abstract][Full Text] [Related]
8. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T cells in type 1 diabetes.
Tsai S; Shameli A; Santamaria P
Adv Immunol; 2008; 100():79-124. PubMed ID: 19111164
[TBL] [Abstract][Full Text] [Related]
10. Perforin facilitates beta cell killing and regulates autoreactive CD8+ T-cell responses to antigen in mouse models of type 1 diabetes.
Trivedi P; Graham KL; Krishnamurthy B; Fynch S; Slattery RM; Kay TW; Thomas HE
Immunol Cell Biol; 2016 Apr; 94(4):334-41. PubMed ID: 26446877
[TBL] [Abstract][Full Text] [Related]
11. Immunotargeting of insulin reactive CD8 T cells to prevent diabetes.
Scott GS; Fishman S; Khai Siew L; Margalit A; Chapman S; Chervonsky AV; Wen L; Gross G; Wong FS
J Autoimmun; 2010 Dec; 35(4):390-7. PubMed ID: 20850948
[TBL] [Abstract][Full Text] [Related]
12. IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells.
Shameli A; Yamanouchi J; Tsai S; Yang Y; Clemente-Casares X; Moore A; Serra P; Santamaria P
Eur J Immunol; 2013 Feb; 43(2):394-403. PubMed ID: 23180662
[TBL] [Abstract][Full Text] [Related]
13. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies.
Faustman DL; Davis M
J Mol Med (Berl); 2009 Dec; 87(12):1173-8. PubMed ID: 19693476
[TBL] [Abstract][Full Text] [Related]
14. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population.
Amrani A; Verdaguer J; Serra P; Tafuro S; Tan R; Santamaria P
Nature; 2000 Aug; 406(6797):739-42. PubMed ID: 10963600
[TBL] [Abstract][Full Text] [Related]
15. Making the most of major histocompatibility complex molecule multimers: applications in type 1 diabetes.
Gojanovich GS; Hess PR
Clin Dev Immunol; 2012; 2012():380289. PubMed ID: 22693523
[TBL] [Abstract][Full Text] [Related]
16. Stage-dependent reactivity of thymocytes to self-peptide--MHC complexes.
Leng Q; Ge Q; Nguyen T; Eisen HN; Chen J
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5038-43. PubMed ID: 17360333
[TBL] [Abstract][Full Text] [Related]
17. Reversal of type 1 diabetes by a new MHC II-peptide chimera: "Single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process.
Lin M; Stoica-Nazarov C; Surls J; Kehl M; Bona C; Olsen C; Brumeanu TD; Casares S
Eur J Immunol; 2010 Aug; 40(8):2277-88. PubMed ID: 20540111
[TBL] [Abstract][Full Text] [Related]
18. Expanding antigen-specific regulatory networks to treat autoimmunity.
Clemente-Casares X; Blanco J; Ambalavanan P; Yamanouchi J; Singha S; Fandos C; Tsai S; Wang J; Garabatos N; Izquierdo C; Agrawal S; Keough MB; Yong VW; James E; Moore A; Yang Y; Stratmann T; Serra P; Santamaria P
Nature; 2016 Feb; 530(7591):434-40. PubMed ID: 26886799
[TBL] [Abstract][Full Text] [Related]
19. Impact of CD8-MHC class I interaction in detection and sorting efficiencies of antigen-specific T cells using MHC class I/peptide multimers: contribution of pMHC valency.
Neveu B; Echasserieau K; Hill T; Kuus-Reichel K; Houssaint E; Bonneville M; Saulquin X
Int Immunol; 2006 Jul; 18(7):1139-45. PubMed ID: 16751231
[TBL] [Abstract][Full Text] [Related]
20. Quantifying immunoregulation by autoantigen-specific T-regulatory type 1 cells in mice with simultaneous hepatic and extra-hepatic autoimmune disorders.
Jamaleddine H; Santamaria P; Khadra A
Immunology; 2020 Nov; 161(3):209-229. PubMed ID: 32687611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
